Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is benefiting from a strong commercial inflection in IMCIVREE, with 3Q26 revenue of $92.1M beating estimates and U.S. sales of $67.5M driven by the acquired hypothalamic obesity launch, which already produced >700 patient start forms and >500 prescribers. Its outlook is further strengthened by a broad international expansion, including Japan’s launch with >1,000 potential patients identified and Europe’s planned 2027 launches, alongside improved access coverage and steady growth in reimbursed patients. Fundamentally, the company also de-risks and enhances long-term value by lowering LG Chem royalties to a flat 1% in exchange for $350M in installments, while a $750M term loan facility and $320.9M of cash support operations and multiple next-generation MC4R shots on goal.

Rhythm Pharmaceuticals is facing a more cautious fundamental outlook despite 3Q26 revenue of $92.1M, because the beat was driven by aHO expansion while management still expects a slower launch trajectory and lowers 2027+ estimates. The LG Chem financing amendment improves flexibility for bivamelagon, but it also brings a $750M term loan, a flat 1% royalty on the MC4R portfolio, and about $550M in additional milestones, raising near-term expense pressure and reducing financial quality. With $320.9M cash at 3Q26, cash flow positivity not modeled until 2029, and commercialization tied to rare-disease patient counts and patent risk, the stock’s fundamentals appear exposed to execution and structural uncertainty.